Maria Rosa Costanzo et al. JCHF 2016;4:95-105

Slides:

Advertisements

Similar presentations

Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.

Advertisements

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Understanding the Heterogeneity in Volume Overload.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Beta-Blockers and Outcome in Heart Failure and Atrial.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.

Discontinuation of medication after nonfatal event: MI

NYHA III* or IV heart failure ACE-I + loop diuretic ± digoxn

Copyright © 2006 American Medical Association. All rights reserved.

Stephen W. Waldo et al. JACC 2008;51:

Muhammad Shahreyar et al. JACEP 2016;j.jacep

The American Heart Association

Noriko Kikuchi et al. JACEP 2016;2:

Change in mean serum creatinine, PAC-guided vs empiric therapy

G. Michael Felker et al. JCHF 2014;2:

Carolyn Y. Ho et al. JCHF 2015;3:

Jose C. Pachon M. et al. JACEP 2015;1:

Belinda Gray et al. JCHF 2013;1:

Simon W. Rabkin et al. JACEP 2017;j.jacep

Wesley T. O’Neal et al. JACEP 2016;2:

Muhammad Shahreyar et al. JACEP 2016;j.jacep

Wayne L. Miller et al. JCHF 2013;1:

Giuseppe Boriani et al. JACEP 2016;2:

John A. Bittl et al. JACC 2016;68:

Jordan B. King et al. JCHF 2016;4:

G. Michael Felker et al. JCHF 2014;2:

Svend A. Mortensen et al. JCHF 2014;2:

Yoshitaka Kimura et al. JACEP 2016;2:

Ivan C. Gerling et al. JCHF 2013;1:

Connie W. Tsao et al. JCHF 2016;4:

Rami Doukky et al. JCHF 2016;4:24-35

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Neal A. Chatterjee et al. JCHF 2014;2:

Gordon R. Reeves et al. JCHF 2017;j.jchf

William T. Abraham et al. JCHF 2015;3:

Peter E. Carson et al. JCHF 2015;3:

Maria R. Costanzo et al. JCHF 2016;4:

Jerry D. Estep et al. JCHF 2013;1:

Simon W. Rabkin et al. JACEP 2017;3:

Emilce Trucco et al. JACEP 2018;j.jacep

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Catherine M. Pound et al. Hospital Pediatrics 2017;7:

Rami Doukky et al. JCHF 2016;4:24-35

Maneesh Sud et al. JCHF 2017;5:

John Rickard et al. JCHF 2013;1:

Jacqueline Baras Shreibati et al. JCHF 2017;j.jchf

Leo F. Buckley et al. JCHF 2016;4:1-8

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

Jordan B. King et al. JCHF 2016;4:

Svend A. Mortensen et al. JCHF 2014;2:

Natasha A. Loghmanpour et al. JCHF 2016;4:

Distribution of responses to the knowledge questions.

Khadijah Breathett et al. JCHF 2017;5:

Connie W. Tsao et al. JCHF 2016;4:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

John A. Sallach et al. JIMG 2009;2:

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Christian Madelaire et al. JCHF 2018;6:

Satoru Kishi et al. JCHF 2014;2:

Khadijah Breathett et al. JCHF 2017;5:

Dennis M. McNamara et al. JCHF 2014;2:

Pamela E. Scott et al. JACC 2018;71:

Jeffrey Senfield et al. JACEP 2017;3:

This figure illustrates the importance of heart failure consideration in primary endpoint trials with hypoglycemic agents. This figure illustrates the.

John P. Boehmer et al. JCHF 2017;5:

Jackson J. Liang et al. JCHF 2014;2:

Orly Vardeny et al. JCHF 2016;4:

Paul A. Gurbel, and Udaya S. Tantry JCHF 2014;2:1-14

Maria R. Costanzo et al. JCHF 2016;4:

Gianluigi Savarese et al. JCHF 2016;4:

Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.

Constantijn Franssen et al. JCHF 2016;4:

Presentation transcript:

Maria Rosa Costanzo et al. JCHF 2016;4:95-105 Primary Endpoint: Time to Heart Failure Event after Discharge Log-rank analysis of the time to first heart failure (HF) event after discharge from index hospitalization up to 90 days in the adjustable ultrafiltration (AUF) (squares) and adjustable loop diuretics (ALD) (triangles) groups. The difference in time to first heart failure event within 90 days after discharge from the index hospitalization was not statistically significant at the 0.05 alpha level (p = 0.106) due to the smaller than originally planned sample size. AQ = aquapheresis; LD = loop diuretics. Maria Rosa Costanzo et al. JCHF 2016;4:95-105 2016 American College of Cardiology Foundation